Join us on the latest episode! Our Guest: Frank Watanabe, President & CEO at Arcutis Biotherapeutics.
What you'll get out of this episode:
- Company Focus: Arcutis Biotherapeutics, under Frank Watanabe, is dedicated to treating inflammatory skin conditions, with three FDA-approved products and a fourth pending.
- Significant Milestones: This year, Arcutis launched two new products and partnered with a primary care company to expand its reach.
- Patient-Centric Approach: Arcutis prioritizes patient needs by involving dermatology practitioners and patient insights directly in decision-making.
- Technological Perspective: While acknowledging AI's potential in drug discovery, Arcutis is focused on tangible, current advancements without prematurely implementing AI.
- Expanding Accessibility: Arcutis is actively working to extend its treatments to Medicare and Medicaid markets to support a broader patient demographic.
To Learn More About Our Guest And Their Company:
LinkedIn https://www.linkedin.com/in/frank-watanabe-419711/
Company LinkedIn https://www.linkedin.com/company/arcutis-inc/
Website https://www.arcutis.com/
Our sponsor for this episode are:
Sage Growth Partners https://sage-growth.com/
BioBreakthroughs is part of the Slice of Healthcare podcast network:
LinkedIn: https://www.linkedin.com/company/sliceofhealthcare/
